Table 3.
Outcomes for the most frequently used medicines in each indication
| Complete response (N) | Partial response (N) | Stabilization (N) | No response (N) | Total (N) | |
|---|---|---|---|---|---|
| Rituximab | |||||
| Complications of organ or tissue transplant, failure or rejection | 3 | 2 | – | 2 | 7 |
| Pemphigus | 1 | 4 | – | 1 | 6 |
| Myasthenia gravis | 2 | – | 1 | 1 | 4 |
| Systemic lupus erythematosus (SLE) | 0 | 2 | – | 2 | 4 |
| Cryoglobulinemic purpura | 2 | 1 | – | – | 3 |
| Lupus nephritis | 1 | 1 | – | 1 | 3 |
| Wegener granulomatosis | – | 3 | – | – | 3 |
| Encephalitis, myelitis and encephalomyelitis | – | 1 | – | 1 | 2 |
| Glomerulonephritis, membranous | – | 1 | – | 1 | 2 |
| Idiopathic thrombocytopenic purpura | – | – | – | 2 | 2 |
| Relapsing polychondritis | – | – | – | 2 | 2 |
| Glomerulonephritis, minimal change disease | 1 | – | – | – | 1 |
| Graft-versus-host disease | – | 1 | – | – | 1 |
| Lymphoproliferative disorder | 1 | – | – | – | 1 |
| Neuromyelitis optica | – | 1 | – | – | 1 |
| Polymyositis | 1 | – | – | – | 1 |
| Polyradiculoneuropathy, chronic inflammatory demyelinating | – | 1 | – | – | 1 |
| Sarcoidosis | – | – | – | 1 | 1 |
| Sjögren syndrome | – | 1 | – | – | 1 |
| Systemic sclerodermia | – | – | 1 | – | 1 |
| Thrombocytopenia in SLE | 1 | – | – | – | 1 |
| Waldenström macroglobulinaemia | – | 1 | – | – | 1 |
| Subtotal (%) | 13 (26.5) | 20 (40.8) | 2 (4.1) | 14 (28.6) | 49 (100) |
| Botulinum toxin | |||||
| Anal fissure | 6 | 4 | – | 3 | 13 |
| Esophageal achalasia | 6 | 1 | – | – | 7a |
| Generalized hyperhidrosis | – | 1 | – | 1 | 2 |
| Eyelid retraction | 1 | – | – | – | 1 |
| Myofascial pain | – | 1 | – | – | 1 |
| Subtotal (%) | 13 (54.2) | 7 (29.1) | – | 4 (16.7) | 24 (100)a |
| Omalizumab | |||||
| Chronic urticaria | 5 | 1 | – | 1 | 7 |
| Food-induced anaphylaxia | 2 | – | – | 1 | 3 |
| Cold-induced urticaria | – | 2 | – | – | 2 |
| Extrinsic allergic asthma | – | 1 | – | – | 1 |
| Nasal polyps | 1 | – | – | – | 1 |
| Subtotal (%) | 8 (57.1) | 4 (28.6) | – | 2 (14.3) | 14 (100) |
Information about the other used medicines is available in annex 3 of the supplementary material
aOne unknown response